Muy poco volumen para la noticia no? Me está mosqueando un poco.
Vamos a ver si se va animando.
The trial met its immunogenicity targets and demonstrated potential to meet the Center for Biological Evaluation and Research (CBER) criteria for accelerated approval.
NVAX
DVAd
Vaya mugiwara OTRA PA TI Y despues dices que yo exageroooooo, jooo que cada vez que leo un art pumpista de estos me dan deseos de subir mi PO, je,je,je
The success of Gilead Sciences (NASDAQ:GILD) in the Hep C space has sparked a great of deal interest in the Hep B space as well. In fact, ....
the Hep B market could turn out to be even bigger than Hep C-- (
Dynavax remains on target to file a revised BLA for Heplisav B early next year. This means that the company will potentially reach commercialization stage by early next year. Given the potential of Heplisav B, it is not surprising to see that investors have been excited about DVAX. Year-to-date, shares have already gained more than 74%, but there could be even more upside as DVAX moves closer to commercialization.
According to GlobalData, the global Hep B vaccine market could reach $1.19 billion by 2022, with the U.S. accounting for nearly 60% of the market. DVAX is initially focusing on the U.S., where it plans to commercialize the drug on its own.
-
If the company is successful in capturing 50% of the total U.S. market of around $600 million by 2022, this would translate to $300 million in sales.
-
Based on just the potential in the U.S., DVAX still looks undervalued despite the nearly 75% gain posted this year.
http://seekingalpha.com/article/3374225-premarket-biotech-digest-familial-hypercholesterolemia-dynavax-bla-track-earnings?app=1&auth_param=ft8lg:1ark5cs:379846458bd72369d355bf5b9042c948&uprof=37
Datos macro USA
US #GDP +2.3% (annualised) in Q2 (+0.6% in Q1): Consumer spending up 2.9%, business investment down 0.6%, Exports +5.3%, Imports +3.5%
GDP Rises 2.3% in Second Quarter; First Quarter Revised Upward
DVAX
Lo estaba leyendo justo ahora! El pumpeo justificado siempre es bienvenido! Me quedo con la última frase :))
DVAX still looks undervalued despite the nearly 75% gain posted this year.
- Los resultados demuestran proteccion para las CUATRO CEPAS.
- Bien contra HA ( hemaglutinina )
- Y parece que bien contra NA - la Neuraminidasa , que es lo que nadie habia conseguido hasta la fecha, NADIE: "we measured neuraminidase-inhibiting (NAI) antibody responses against seasonal influenza viruses for the first time, and were able to detect significant NAI antibody responses to all four influenza strains, including strong responses against the B virus strains"
Asi que el resultado es super de puta madre
NVAX
NVAX
Vamos a ver a dónde llevan el precio hoy. Ya estoy tenso.
NVAX
El PM lo está reflejando bien, puede ser un gran dia para las NVAX :-)
"Buf, se me está haciendo más largo que un dia sin bolsa"
Algun usano ya esta mosca porque no tiene un super premarket ... bueno, de hecho, hace 13 minutos que en nasdaq.com dice que no se cruza ningun paquete en premarket ...
No estara HALTED, verdad?
NVAX
